Beyond Novartis’s own disclosures, separate reporting points to continued public concern around Zolgensma safety following confirmed tumor cases in recipients. The additional attention highlights the gap that can emerge between label language on theoretical risk and stakeholder expectations for real-world evidence and transparency. The episode underscores a recurring gene-therapy industry challenge: communicating risk in the context of lifelong viral-vector persistence while ensuring patients are fully informed and monitored. It also raises pressure for standardized reporting of integration findings and long-term follow-up endpoints. While the underlying prescribing risk framework remains consistent, the renewed spotlight suggests regulators and the market will demand stronger clarity on incidence, integration signals, and case-by-case clinical interpretation.